ArticleFrontiers in medicine2026
A clinical observation of carbon dioxide laser-assisted deep sclerectomy for Posner-Schlossman Syndrome.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to preliminarily evaluate the clinical efficacy and safety of carbon dioxide laser-assisted deep sclerectomy (CLASS) in patients with medically refractory Posner-Schlossman Syndrome (PSS). Methods: Six patients (six eyes) with poorly controlled PSS were included. All patients underwent CLASS under local anesthesia and were followed up for 18 months. Primary outcome measures included intraocular pressure (IOP), best-corrected visual acuity (BCVA), retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness, visual field parameters, and surgical complications. Results: The mean preoperative IOP was 28.30 ± 5.16 mmHg. Postoperative IOP decreased significantly, with a mean IOP of 14.56 ± 1.82 mmHg at the final 18-month follow-up. Visual acuity recovered to or exceeded preoperative levels in all cases. No statistically significant differences were observed in RNFL or GCC thickness at any postoperative time point (6, 12, and 18 months) compared to preoperative values. Visual field indices (MD, PSD) remained stable throughout follow-up. Postoperative complications included transient hypotony (three eyes), peripheral anterior synechiae (two eyes, successfully treated with laser), transient shallow anterior chamber (one eye), and mild anterior chamber reaction (one eye). All complications were managed conservatively without sequelae, and no serious adverse events occurred. Conclusion: CLASS surgery provides effective and sustained IOP reduction in patients with refractory PSS. It demonstrates favorable structural and functional preservation of the optic nerve over the mid-term follow-up, with a manageable profile of minor complications. These preliminary findings suggest CLASS is a promising minimally invasive surgical option for this condition, though its long-term efficacy warrants confirmation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.